Author: Lapchak, Paul A

Source: Expert Opinion on Investigational Drugs, Volume 17, Number 8, August 2008 , pp. 1175-1186(12)

Publisher: Informa Healthcare

Abstract:

Background: Carbamylated erythropoietin (CEPO) is a modified erythropoietin molecule not affecting hematocrit. It is a potentially important pharmacological agent that may be applied to the treatment of several diseases affecting central and peripheral system neurons. Objective: Carbamylated erythropoietin is a prime candidate for development because of its potent cell survival and function enhancing effects. This article reviews the preclinical development profile of CEPO in animal models to determine whether further clinical development is justified. Methods: The review spans a detailed analysis of patents and scientific publications related to CEPO in animal models. Results/conclusions: Use of CEPO in treating diseases such as stroke and traumatic brain and spinal cord injuries is important because these conditions affect millions of patients every year. Extensive preclinical studies support further clinical studies of CEPO for acute ischemic stroke. However, further studies are required for testing CEPO in patients with many other indications.

Keywords: clinical trial; diabetes; erythropoietin; hematopoietic; neuroprotection; recovery; spinal cord injury; stroke; traumatic brain injury

Document Type: Research article

DOI: http://dx.doi.org/10.1517/13543784.17.8.1175

Publication date: 2008-08-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Lapchak, Paul A

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers